Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Kim
Peter J Neumann

Showing results (121-130 of 436) with videos related to

Pageof 44
Sort By:
Health Affairs (Project Hope)|April 12, 2012
Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countriesPeter J Neumann, Sarah K Bliss, James D Chambers
Medical Decision Making : an International Journal of the Society for Medical Decision Making|December 1, 2025
When Do Published Cost-Effectiveness Analyses Include Societal Costs? An Empirical Analysis, 2013-2023Divya Patil, Bengt Liljas, Peter J Neumann, et al.
Pharmacoeconomics|May 17, 2023
Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention StrategyDavid D Kim
The Lancet. Public Health|March 1, 2024
The role of simulation modelling in public health policy evaluationDavid D Kim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 14, 2011
Cost-utility analyses of diagnostic laboratory tests: a systematic reviewChiHui Fang, Hansel J Otero, Dan Greenberg, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 13, 2015
The lag from FDA approval to published cost-utility evidenceJames D Chambers, Teja Thorat, Junhee Pyo, et al.
Health Policy (Amsterdam, Netherlands)|September 15, 2004
Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation studyDan Greenberg, Ameet Bakhai, Peter J Neumann, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|July 13, 2006
What affects the quality of economic analysis for life-saving investments?Robert W Hahn, Katrina Kosec, Peter J Neumann, et al.
Health Affairs (Project Hope)|August 5, 2015
Private payers disagree with Medicare over medical device coverage about half the timeJames D Chambers, Matthew Chenoweth, Teja Thorat, et al.
Health Affairs (Project Hope)|October 6, 2010
A flexible approach to evidentiary standards for comparative effectiveness researchLouis P Garrison, Peter J Neumann, Paul Radensky, et al.
Pageof 44

Showing results (121-130 of 436) with videos related to

Sort By:
Pageof 44
Health Affairs (Project Hope)|April 12, 2012
Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countriesPeter J Neumann, Sarah K Bliss, James D Chambers
Medical Decision Making : an International Journal of the Society for Medical Decision Making|December 1, 2025
When Do Published Cost-Effectiveness Analyses Include Societal Costs? An Empirical Analysis, 2013-2023Divya Patil, Bengt Liljas, Peter J Neumann, et al.
Pharmacoeconomics|May 17, 2023
Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention StrategyDavid D Kim
The Lancet. Public Health|March 1, 2024
The role of simulation modelling in public health policy evaluationDavid D Kim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 14, 2011
Cost-utility analyses of diagnostic laboratory tests: a systematic reviewChiHui Fang, Hansel J Otero, Dan Greenberg, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 13, 2015
The lag from FDA approval to published cost-utility evidenceJames D Chambers, Teja Thorat, Junhee Pyo, et al.
Health Policy (Amsterdam, Netherlands)|September 15, 2004
Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation studyDan Greenberg, Ameet Bakhai, Peter J Neumann, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|July 13, 2006
What affects the quality of economic analysis for life-saving investments?Robert W Hahn, Katrina Kosec, Peter J Neumann, et al.
Health Affairs (Project Hope)|August 5, 2015
Private payers disagree with Medicare over medical device coverage about half the timeJames D Chambers, Matthew Chenoweth, Teja Thorat, et al.
Health Affairs (Project Hope)|October 6, 2010
A flexible approach to evidentiary standards for comparative effectiveness researchLouis P Garrison, Peter J Neumann, Paul Radensky, et al.
Pageof 44